ATE253373T1 - Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen - Google Patents

Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen

Info

Publication number
ATE253373T1
ATE253373T1 AT98937862T AT98937862T ATE253373T1 AT E253373 T1 ATE253373 T1 AT E253373T1 AT 98937862 T AT98937862 T AT 98937862T AT 98937862 T AT98937862 T AT 98937862T AT E253373 T1 ATE253373 T1 AT E253373T1
Authority
AT
Austria
Prior art keywords
physiologically acceptable
complexes
salts
vanadium compounds
acceptable vanadium
Prior art date
Application number
AT98937862T
Other languages
English (en)
Inventor
Conradus Ghosal Gho
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Application granted granted Critical
Publication of ATE253373T1 publication Critical patent/ATE253373T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98937862T 1997-07-29 1998-07-29 Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen ATE253373T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
PCT/NL1998/000431 WO1999006056A1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes

Publications (1)

Publication Number Publication Date
ATE253373T1 true ATE253373T1 (de) 2003-11-15

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937862T ATE253373T1 (de) 1997-07-29 1998-07-29 Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen

Country Status (22)

Country Link
US (2) US6579540B1 (de)
EP (1) EP1001792B1 (de)
JP (1) JP2001511454A (de)
CN (1) CN1104244C (de)
AT (1) ATE253373T1 (de)
AU (1) AU738701B2 (de)
BR (1) BR9811298A (de)
CA (1) CA2298645C (de)
CZ (1) CZ299716B6 (de)
DE (1) DE69819514T2 (de)
DK (1) DK1001792T3 (de)
EA (1) EA002574B1 (de)
ES (1) ES2207851T3 (de)
ID (1) ID24870A (de)
IL (2) IL134259A0 (de)
NL (1) NL1006681C2 (de)
NO (1) NO20000446L (de)
NZ (1) NZ502613A (de)
PL (1) PL338415A1 (de)
PT (1) PT1001792E (de)
TR (1) TR200000349T2 (de)
WO (1) WO1999006056A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
AU1898700A (en) * 1999-12-20 2001-07-03 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and NA+/H+ exchange inhibitor
WO2003041703A2 (en) * 2001-11-16 2003-05-22 Gho Holding B.V. Use of a flavonoid for the treatment of burns
EP2275560A3 (de) 2007-01-31 2012-01-25 BASF Plant Science GmbH Transgene Pflanzen, enthaltend als Transgen ein Mitglied der REMORIN Gen Familie oder eine Konsenssequenz davon, mit verbesserten Eigenschaften bezüglich des Ertrags und Verfahren zu ihrer Herstellung
MX2009011716A (es) 2007-05-03 2009-12-11 Basf Plant Science Gmbh Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas.
US8697947B2 (en) 2007-07-20 2014-04-15 Basf Plant Science Gmbh Plants having increased yield-related traits and a method for making the same
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
BRPI0818482A2 (pt) 2007-10-29 2014-10-07 Basf Plant Science Gmbh Método para intensificar as características relacionadas ao redimento, constructo, uso de um constructo, planta , parte de planta ou célula de planta, método para a produção de uma planta transgênica, planta transgênica, partes colhíves de uma planta, produtos, e, uso de um ácido nucleico
AU2009243552A1 (en) 2008-05-05 2009-11-12 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
BR112012017535A2 (pt) 2010-01-15 2019-09-24 Of Medicine And Dentistry Of New Jersey University uso de compostos de vanádio para cicatrização de osso
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
JP5992917B2 (ja) 2010-12-10 2016-09-14 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー インスリン疑似剤コンポジットで被覆される埋め込み型デバイスおよびその方法
BR112013022907A2 (pt) 2011-03-07 2016-09-13 Cfm Pharma Holding Bv composição farmacêutica
US9931348B2 (en) * 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
ID24870A (id) 2000-08-31
EA200000176A1 (ru) 2000-10-30
AU738701B2 (en) 2001-09-27
EA002574B1 (ru) 2002-06-27
NL1006681C2 (nl) 1999-02-08
DE69819514T2 (de) 2004-09-23
TR200000349T2 (tr) 2000-09-21
PL338415A1 (en) 2000-11-06
CZ299716B6 (cs) 2008-10-29
ES2207851T3 (es) 2004-06-01
NO20000446L (no) 2000-03-24
NZ502613A (en) 2001-08-31
EP1001792B1 (de) 2003-11-05
CN1270525A (zh) 2000-10-18
BR9811298A (pt) 2000-08-29
US6579540B1 (en) 2003-06-17
DE69819514D1 (de) 2003-12-11
IL134259A0 (en) 2001-04-30
AU8650598A (en) 1999-02-22
JP2001511454A (ja) 2001-08-14
IL134259A (en) 2010-02-17
PT1001792E (pt) 2004-03-31
EP1001792A1 (de) 2000-05-24
CZ2000326A3 (cs) 2000-07-12
WO1999006056A1 (en) 1999-02-11
DK1001792T3 (da) 2004-01-19
CA2298645C (en) 2004-05-18
US20030211170A1 (en) 2003-11-13
CN1104244C (zh) 2003-04-02
CA2298645A1 (en) 1999-02-11
NO20000446D0 (no) 2000-01-28

Similar Documents

Publication Publication Date Title
ATE253373T1 (de) Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
BR0109703A (pt) Derivados de piperazina
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
TR200101649T2 (tr) Piperazin türevleri.
WO1998009599A3 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
SE9802209D0 (sv) Novel compounds
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
AU3401093A (en) Therapeutic agent for threatened abortion
FR2794976B1 (fr) Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
WO2001016096A3 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
TR200201654T2 (tr) Benzamidin türevleri.
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
ATE204294T1 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001792

Country of ref document: EP

REN Ceased due to non-payment of the annual fee